- Cat. No.
- A12948
UNC1215
UNC1215 is a potent, selective antagonist of L3MBTL3 with cellular activity.
In stock
View Details
-
-
- Cat. No.
- A13717
UNC 669
UNC669 is a small-molecule antagonist of methyl-lysine (KMe) reader protein with selectivity for L3MBTL1 and L3MBTL3 (IC50 of 4.2μM and 3.1μM respectively)
In stock View Details -
- Cat. No.
- A17014
MZ1
MZ1 is a potent inducer of reversible, long-lasting and selective removal of BRD4 over BRD2 and BRD3.
In stock View Details -
- Cat. No.
- A23991
AR420626
AR420626 is a selective agonist of free fatty acid receptor 3 (FFAR3, also known as GPR41), with an IC₅₀ of 117 nM. It demonstrates anti-inflammatory, antitumor, and antidiabetic activities. AR420626 improves neurogenic diarrhea by modulating neural pathways mediated by nicotinic acetylcholine receptors (nAChRs). In cancer models, it suppresses the growth of HepG2 xenografts and inhibits hepatoma cell proliferation through apoptosis induction. Additionally, AR420626 mitigates allergic asthma and eczema and enhances glucose uptake by activating FFAR3-mediated Ca²⁺ signaling, offering potential therapeutic benefits in metabolic disorders such as diabetes.
In stock View Details -
- Cat. No.
- A26666
UNC3866 TFA
UNC3866 TFA is a selective antagonist of the CBX7-H3 interaction, exhibiting a potency with an IC50 value of 66±1.2 nM as determined by AlphaScreen assays. This compound shows over 100-fold selectivity for CBX7 compared to other members of the methyl-lysine reader panel. UNC3866 TFA is valuable for research applications focused on elucidating the role of CBX7 in epigenetic regulation and potential therapeutic strategies targeting this pathway.
In stock View Details -
- Cat. No.
- A37081
C-82
C-82 is a selective antagonist of CBP/β-catenin interaction, designed to inhibit the binding of β-catenin to CBP while promoting its association with p300. This compound effectively modulates the Wnt signaling pathway, making it a valuable tool for research in cancer biology and developmental processes. C-82 serves as an important reagent for studies investigating the role of β-catenin in transcriptional regulation and related disease mechanisms.
In stock View Details -
- Cat. No.
- A40623
BRD4 Inhibitor-37
BRD4 Inhibitor-37 is a selective antagonist of the Epigenetic Reader Domain BRD4, demonstrating significant anticancer activity. With an IC50 ranging from 0.05-0.1 μM in binding assays and a GI50 of 0.1-0.3 μM in cellular models, this compound effectively impedes the c-Myc signaling pathway, a critical downstream target of BRD4. Its selectivity across multiple bromodomain proteins positions BRD4 Inhibitor-37 as an important tool for investigating BET protein functions in cancer research and therapeutic development.
In stock View Details